Adjuvant interferon-alpha for melanoma revisited: News from old and new studies

C. J.A. Punt; A. M.M. Eggermont

doi:10.1023/A:1013592219007

Adjuvant interferon-alpha for melanoma revisited: News from old and new studies

C. J.A. Punt, A. M.M. Eggermont

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

Abstract

Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNα) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNα, the duration of IFNα administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNα does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNα trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNα is still immature. Therefore currently the routine use of IFNα cannot be recommended outside the scope of clinical trials.

Original language	English
Pages (from-to)	1663-1666
Number of pages	4
Journal	Annals of Oncology
Volume	12
Issue number	12
DOIs	https://doi.org/10.1023/A:1013592219007
Publication status	Published - 2001
Externally published	Yes

Keywords

Adjuvant therapy
Interferon-alfa
Melanoma
Review low-dose IFNα trials

Access to Document

10.1023/A:1013592219007

Cite this

@article{1b5c77c9899743df96755163ee131c35,

title = "Adjuvant interferon-alpha for melanoma revisited: News from old and new studies",

abstract = "Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNα) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNα, the duration of IFNα administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNα does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNα trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNα is still immature. Therefore currently the routine use of IFNα cannot be recommended outside the scope of clinical trials.",

keywords = "Adjuvant therapy, Interferon-alfa, Melanoma, Review low-dose IFNα trials",

author = "Punt, {C. J.A.} and Eggermont, {A. M.M.}",

year = "2001",

doi = "10.1023/A:1013592219007",

language = "English",

volume = "12",

pages = "1663--1666",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - Adjuvant interferon-alpha for melanoma revisited

T2 - News from old and new studies

AU - Punt, C. J.A.

AU - Eggermont, A. M.M.

PY - 2001

Y1 - 2001

N2 - Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNα) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNα, the duration of IFNα administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNα does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNα trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNα is still immature. Therefore currently the routine use of IFNα cannot be recommended outside the scope of clinical trials.

AB - Currently the data from 12 randomised phase III trials investigating the role of interferon-alpha (IFNα) in patients with stage II-III high-risk melanoma are available. The most prominent differences between these trials concern the dose of IFNα, the duration of IFNα administration, and the stage of disease. Some of these trials have not yet reached maturity, but despite this the positive results from some immature trials have attracted considerable attention. When only data from mature trials is considered, one may conclude that the use of high-dose IFNα does prolong disease-free survival (DFS) but not overall survival (OS). Combined data from low-dose IFNα trials does not suggest a benefit in either DFS or OS. A trial with intermediate-dose IFNα is still immature. Therefore currently the routine use of IFNα cannot be recommended outside the scope of clinical trials.

KW - Adjuvant therapy

KW - Interferon-alfa

KW - Melanoma

KW - Review low-dose IFNα trials

UR - http://www.scopus.com/inward/record.url?scp=0035700212&partnerID=8YFLogxK

U2 - 10.1023/A:1013592219007

DO - 10.1023/A:1013592219007

M3 - Review article

C2 - 11843241

AN - SCOPUS:0035700212

SN - 0923-7534

VL - 12

SP - 1663

EP - 1666

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -

Adjuvant interferon-alpha for melanoma revisited: News from old and new studies

Abstract

Keywords

Access to Document

Fingerprint

Cite this